Voucher sale brings $110M payday for Spark Therapeutics
By John George Senior Reporter, Philadelphia Business Journal
Spark Therapeutics is taking advantage of a perk in a Food and Drug Administration program for a nine-figure payday.
The Philadelphia gene therapy company said Monday it has sold its rare pediatric disease priority review voucher to Jazz Pharmaceuticals for $110 million. Spark will receive the payment once the transaction closes.